Accuray Incorporated (NASDAQ:ARAY) Shares Bought by Foundry Partners LLC

Foundry Partners LLC grew its position in Accuray Incorporated (NASDAQ:ARAY - Free Report) by 51.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,187,160 shares of the medical equipment provider's stock after purchasing an additional 741,900 shares during the quarter. Foundry Partners LLC owned approximately 2.18% of Accuray worth $3,937,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Armistice Capital LLC acquired a new stake in Accuray during the 2nd quarter worth $910,000. Price T Rowe Associates Inc. MD increased its holdings in Accuray by 9.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 73,146 shares of the medical equipment provider's stock valued at $181,000 after acquiring an additional 6,583 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of Accuray during the 2nd quarter worth approximately $132,000. Allspring Global Investments Holdings LLC increased its position in Accuray by 6,480.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 35,007 shares of the medical equipment provider's stock worth $64,000 after buying an additional 34,475 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Accuray by 253,483.3% in the second quarter. Nisa Investment Advisors LLC now owns 15,215 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 15,209 shares during the last quarter. 64.08% of the stock is currently owned by institutional investors and hedge funds.

Accuray Trading Up 2.1 %

Shares of ARAY stock traded up $0.04 during mid-day trading on Friday, reaching $1.93. The company's stock had a trading volume of 638,787 shares, compared to its average volume of 662,232. The company has a quick ratio of 0.87, a current ratio of 1.63 and a debt-to-equity ratio of 3.59. The firm has a market capitalization of $194.10 million, a PE ratio of -11.21 and a beta of 1.40. The company's 50 day simple moving average is $1.85 and its 200-day simple moving average is $1.83. Accuray Incorporated has a 12-month low of $1.40 and a 12-month high of $3.05.

Accuray (NASDAQ:ARAY - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%. The firm had revenue of $101.55 million for the quarter, compared to the consensus estimate of $98.10 million. During the same quarter in the previous year, the firm posted ($0.03) EPS. On average, research analysts predict that Accuray Incorporated will post 0.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut shares of Accuray from a "buy" rating to a "hold" rating in a research note on Friday, November 15th.

Accuray Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.